BRAF and non-small cell lung carcinoma: The European Society of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) guidelines recommend the use of BRAF/MEK inhibitors in first or subsequent lines therapy for NSCLC that harbors a V600E mutation, based on phase 2 trials (26).